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Abstract 
Background: Chronic obstructive pulmonary disease (COPD) is a disease of increasing 
significance in terms of economic and social burden due to its increasing prevalence and high 
costs. Direct costs of COPD are mostly associated with hospitalization expenditures. In this 
study, our objective was to investigate the costs of hospitalization and factors affecting these 
costs in patients hospitalized due to acute exacerbation of COPD (AECOPD).  
Methods: A total of 284 patients hospitalized AECOPD were included in the study. Data 
were examined retrospectively using the electronic hospital charts.  
Results: Mean duration of hospitalization was 11.38 ± 6.94 days among study patients. Rates 
of  admission  to  the  intensive  care unit,  initiation of non-invasive mechanical  ventilation 
(NIMV) and invasive mechanical ventilation (MIV) were 37.3% (n=106), 44.4% (n=126) and 
18.3% (n=52) respectively. The rate of mortality was 14.8% (n=42). Mean cost of a single 
patient hospitalized for an AECOPD was calculated as $1765 ± 2139. Mean cost of admission 
was $889 ± 533 in standard ward, and $2508 ± 2857 in intensive care unit (ICU). The duration 
of hospitalization, a FEV1% predicted value below 30%, having smoked 40 package-years or 
more, the number of co-morbidities, NIMV, IMV, ICU, exitus and the number of hospitali-
zations in the past year were among the factors that increased costs significantly. Hospital 
acquired pneumonia, chronic renal failure and anemia also increased the costs of COPD 
significantly.  
Conclusion: The costs of treatment increase with the severity of COPD or with progression 
to a higher stage. Efforts and expenditures aimed at preventing COPD exacerbations might 
decrease the costs in COPD. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) 
is one of the most important causes of morbidity and 
mortality overall the world. The prevalence of COPD 
is expected to increase rapidly in the near future due 
to the persistence of risk factors of COPD and changes 
in  the  age  characteristics  of  the  world  population. 
COPD  was  the  most  common  6th  cause  of  death 
worldwide in 1990; however it is assumed to range 
the 3rd in 2020 [1]. 
Individuals  with  COPD  typically  experience 
acute exacerbations, which may result in hospitaliza-
tion. Acute exacerbation of COPD (AECOPD) is de-
fined as “an acute worsening in the patient’s condi-
tion from the stable state, which is sustained and may 
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warrant the patient to seek additional treatment” [2]. 
COPD  is  a  disease  that  brings  significant  eco-
nomic and social burden due to its both direct and 
indirect costs [3]. Direct costs include drug expendi-
tures,  diagnostic  expenditures,  expenditures  associ-
ated  with  disease  follow-up,  out-patients  clinic, 
emergency  ward,  and  hospitalizations  [4-8].  It  has 
been reported that the direct cost of COPD has been 
$29.5 billion whereas total cost has been $49.9 billion 
in the year 2002 in the United States of America (USA) 
[8]. In the European Union, the total direct costs of 
respiratory disease are estimated to be about 6% of the 
total healthcare expenditures, with COPD accounting 
for 56% (38.6 billion Euros) of this cost of respiratory 
disease [9].  
In this study, our objective was to examine the 
costs  of  hospitalization  and  factors  affecting  these 
costs in patients referring to the clinic of chest diseases 
and hospitalized due to AECOPD.  
Methods 
Patients 
All  patients  hospitalized  primarily  due  to 
AECOPD  at  the  Department  of  Chest  Diseases  of 
Zonguldak  Karaelmas  University  Medical  School 
between the dates September 2010 and August 2011 
were included in the study. The Ethic Committee of 
our institution approved the study protocol. The di-
agnosis of COPD was established by the GOLD crite-
ria [3] in our hospital. Patients presenting with clinical 
symptoms suggestive of COPD and FEV1/FVC < 70% 
in  spirometric  examination  were  diagnosed  with 
COPD. The diagnosis was established by the clinical 
findings in the presence of risk factors for COPD in 
patients who could not comply with the spirometric 
examination. Demographic features, clinical data and 
hospitalization bills of a total of 284 hospitalization 
files  were  screened  retrospectively  using  the  elec-
tronic  hospital  charts.  Bills  were  evaluated  in  two 
categories as ward bills and intensive care unit (ICU) 
bills.  Ward  bills  were  examined  in  four  categories 
consisting  of  laboratory,  disbursement,  drug  and 
clinical  (diagnostic  procedures,  interventions  and 
oxygen  therapy)  procedures.  Since  the  study  was 
performed in a university hospital, prices of all ex-
penditures  were  determined  by  the  state.  Expendi-
tures associated with the ICU were not sub-divided 
into categories, since these expenditures determined 
by the state were at fixed prices according to disease 
severity and number of days of hospitalization. Ex-
penditures  were  calculated  in  US  dollars  (exchange 
rate at the time of the study was 1.89 Turkish liras per 
US dollars, 0.76 Euro per US dollars).  
Statistical analysis 
Statistical analysis was performed using the Sta-
tistical  Package  for  Social  Sciences  11.0  (SPSS  Inc., 
Chicago,  IL,  USA)  software.  Continuous  variables 
were summarized as means (± SD). Variables between 
two  groups  were  compared  with  an  unpaired  Stu-
dent’s t  test.  Distribution  of categorical  groups was 
examined with the Kolmogorov Smirnov test. Mann 
Whitney U test was used to study the difference be-
tween  variables  when  normal  distribution  did  not 
exist in at least one of  the groups. All values  were 
two-sided. A P value less than 0.05 was considered 
statistically significant. 
Results 
The  284  hospitalization  files  included  in  the 
study belonged to a total of 242 patients due to re-
current  hospitalizations  within  one  year.  We  evalu-
ated  the  demographic  features  of  study  population 
(Table 1). This study population is unique since the 
most of the patients were coal miners (44.1%). Addi-
tionally,  study  patients  were  quite  old  (mean  age 
70.35 ±  10.65)  and  male  dominant,  as  we  expected. 
Demographic  characteristics  of  study  sample  were 
summarized in Table 1. History of one or more than 
one hospitalizations in the past year was present in 
71.1%  (n=101)  of  the  patients.  Mean  amount  of 
smoking was 42.69 ± 22.91 (4-140) package-years in 
patients  with  history  of  smoking.  Evaluation  of  the 
clinical  data  demonstrated  that  non-invasive  me-
chanical ventilation (NIMV) had been administered in 
almost half of the patients (Table 2).  
Mean cost of a single patient hospitalized in the 
department  of  chest  diseases  due  to  AECOPD  has 
been determined as $1765 ± 2139. The majority of this 
figure  consisted  of  medications  and  clinical  proce-
dures in standard ward patients (Table 3). 
Factors  that  increased  costs  significantly  in-
cluded  the  number  of  hospitalizations,  prolonged 
periods  of  hospitalization,  having  co-morbidities,  a 
FEV1% predicted value lower than 30%, smoking 40 
package-years or more, having NIMV, having inva-
sive mechanical ventilation (IMV), hospitalization in 
the  ICU  and  exitus  (Table  4).  Among  the 
co-morbidities hospital acquired pneumonia, chronic 
renal failure and anemia increased the costs of COPD 
significantly (Table 5). There was no significant dif-
ference in clinical costs, laboratory costs and costs of 
consumables when compared between patients with 
and  without  hospital  acquired  pneumonia  (HAP). 
Cost of medications was $391 ± 339$ in patients with 
HAP (n=60), and $202 ± 129 in patients without HAP 
(n=205) (p<0.001). Int. J. Med. Sci. 2012, 9 
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Table 1. Demographic characteristics of study patients. 
Gender - no (%)    
  Male  168 (69.4) 
  Female  74 (30.6) 
Age - year   
  Mean  70.35 ± 10.65 
  Range  34-90 
Occupation - no (%)   
  Coal miner  105 (44.1) 
  Housewife  71 (29.8) 
  Workman  23 (9.7) 
  Officer  8 (3.4) 
  Other  31 (13.0) 
Smoking - no (%)   
  Current smoker  20 (8.4) 
  Ex-smoker  128 (54.0) 
  Non-smoker  89(37.6) 
 
 
 
Table 2. Clinical features of study patients. 
Intensive care unit patient- n/n total (%)  106/284 (37.3) 
Mechanical ventilation   
Patient receiving NIMV - n/n total (%)  126/284 (44.4) 
Patient receiving IMV - n/n total (%)  52/284 (18.3) 
Mean duration of hospitalization- days 
(min-max.) 
11.38±6.94 (1-49) 
Mean duration of hospitalization in ICU- days 
(min-max.) 
7.19±7.05 (1-43) 
Mean duration of hospitalization in standard 
ward- days (min- max) 
9.32±5.17 (1-36) 
Mean FEV1% predicted value- (n)  43.86±17.04 (135) 
Mortality- n/n total (%)  42/284 (14.8)  
 
 
 
 
Table 3. Mean cost of patients hospitalized for AECOPD 
Unit of admission  Cost- $  Daily cost- $  n 
Mean cost in standard ward  889±533  98±37    265 
  Laboratory  167±140     
  Consumables  56±73     
  Drugs  245±212     
  Clinical  422±262     
Mean cost of intensive care 
unit 
2508±2857  330±181  106 
Total mean cost  1765±2139  147±118  284 
 
 
 
Table 4. Factors associated with hospitalization costs in 
patients with AECOPD. 
Parameter  Cost- $ 
present  absent  p 
Number of hospitali-
zations* >1 - (n) 
2082±2852 (69)  1126±1068 (98)  0.003 
Number of hospitali-
zations* >2- (n) 
2181±3104 (43)  1292±1484 (124)  0.014 
Hospitalization longer 
than 7 days- (n) 
2193±2384 (198)  782±805 (86)  <0.001 
FEV1% predicted value 
below 50%- (n) 
1007±1003 (87)  1240±969 (48)  0.189 
FEV1% predicted value 
below 30%- (n) 
1467±1012 (33)  1057±958(102)  0.037 
History of smoking- (n)  1895±2342 (174)  1487±1652 (105)  0.090 
Smoking 40 pack-
age-years or more- (n) 
2266±2858 (101)  1383±1186 (71)  0.015 
Presence of 
co-morbidities- (n) 
1834±2191 (266)  748±372 (18)  0.001 
Presence of more than 
one comorbidities- (n) 
2041±2434 (190)  1209±1189 (94)  <0.001 
Admission to intensive 
care unit- (n) 
3217±2914 (106)  901± 512 (178)  <0.001 
NIMV- (n)  2185 ±1848 (126)  1431±2296 (158)  0.002 
IMV- (n)  4415±3465 (52)  1172±1010 (232)  <0.001 
Exitus- (n)  4033±3510 (42)  1372±1492 (242)  <0.001 
*Number of hospitalizations due to acute exacerbation of COPD in 
the past one year  
 
Table 5. Co-morbidities associated with hospitalization 
costs in patients with AECOPD. 
  Cost- $ 
present  absent  p 
Hypertension- (n)  1627±1696 (n=122)  1870±2419 (n=162)  0.321 
Communi-
ty-acquired pneu-
monia- (n) 
1907±1931 (n=115)  1669±2270 (n=169)  0.358 
Congestive heart 
failure- (n) 
3597±4591 (n=74)  3246±3829 (n=211)  0.557 
Hospital-acquired 
pneumonia - (n) 
3293±3358 (n=70)  1266±1187 (n=214)  <0.001 
Diabetes mellitus- 
(n) 
1555±1754 (n=64)  1827±2238 (n=220)  0.371 
Pneumoconiosis- 
(n) 
1813±2365 (n=49)  1756±2094 (n=235)  0.864 
Pulmonary embo-
lism- (n) 
1743±1883 (n=35)  1769±2176 (n=249)  0.946 
Coronary artery 
disease- (n) 
1449±1381 (n=25)  1796±2198 (n=259)  0.522 
Sleep apnea syn-
drome- (n) 
1575±1341 (n=18)  1778±2183 (n=266)  0.785 
Chronic renal fail-
ure - (n) 
2280 ± 1697 (n=17)  1733±2162 (n=267)  0.026 
Malignancy- (n)  2436±2313 (n=16)  1726±2126 (n=268)  0.073 
Anemia- (n)  3896±3393 (n=13)  1663±2014 (n=271)  0.002 Int. J. Med. Sci. 2012, 9 
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Discussion 
Several studies have been performed about the 
cost of COPD; however there are few studies investi-
gating the factors affecting this cost. In our study, we 
determined that the mean cost of a patient admitted to 
the  clinic  of  chest  diseases  (standard  ward  and/or 
respiratory intensive care unit) is $1765 ± 2139. Study 
results have demonstrated that the number and dura-
tion  of  hospitalization,  FEV1  values,  smoking,  me-
chanical ventilation, hospitalization in the ICU, exitus 
and co-morbidities affected the cost of COPD signifi-
cantly.  
Direct cost of COPD was 18 billion Dollars in the 
year 2002 in USA; whereas this figure has increased 
up to 29.5 billion Dollars in the year 2010. Most of the 
direct  cost  has  been  reported  to  consist  of  hospital 
expenses [8]. One study performed in the USA has 
separated  hospitalized  patients  according  to  the 
presence  or  absence  of  COPD;  and  costs  were  2.4 
times higher in patients with COPD (n=42,472) com-
pared to those without COPD (n=1,221,615) [10].  
Costs of patients hospitalized for COPD varies 
greatly  by  the  countries.  One  study  performed  in 
Singapore  has  determined  that  the  mean  cost  of  a 
COPD  patient  hospitalized  in  the  standard  ward 
within a period of 5 years was $7184 [11]. Mean cost of 
COPD has been calculated as $2008 in a cost-analysis 
study performed by Dalal et al. in the USA on 37089 
patients with COPD [12]. Cost has been reported as 
$305 in out-patients, $327 in emergency ward patients, 
$9745 in standard ward patients and $33440 in inten-
sive care unit patients. In the study of Ozkaya et al. 
performed in Turkey, mean duration has been found 
as $718 ± 364 per admission among patients hospital-
ized  for  AECOPD  [13].  However,  costs  of  patients 
admitted due to AECOPD are expected to be greater 
since ICU patients who constitute the majority of costs 
have not been included. Another study from Turkey 
has demonstrated that patients with AECOPD were 
responsible from the great majority of total costs of 
patients admitted to the clinic of chest diseases and 
that mean cost was $997[14]. The rates of COPD costs 
figured out in our study are quite lower compared to 
those of the other countries.  
A retrospective study performed on a total of 413 
COPD patients has grouped patients by the results of 
spirometric examination, and reported that the hos-
pital costs were $680, $2658 and $6770 in patients with 
mild, moderate and severe COPD, respectively [15]. 
Although most of the patients who could not perform 
spirometry or cooperate during spirometry and thus 
had  missing  spirometric  values  were  very  severe 
COPD patients that required admission to intensive 
care unit; costs were significantly higher in patients 
with a FEV1% predicted value lower than 30%. This 
has  suggested  a  strong  relationship  between  spiro-
metric values and costs of COPD.  
A multi-centered study performed in China has 
evaluated  the  data  of  439  patients  hospitalized  for 
AECOPD retrospectively and noted that age (p<0.01) 
and days of hospitalization (p<0.01) correlated posi-
tively with the costs of COPD. A total of 321 patients 
have been further examined and it has been reported 
that NIMV (p<0.01), MV (p<0.01) and admission to 
ICU (p<0.01) increased the cost of COPD significantly 
[16]. Results of this Chinese study on the factors af-
fecting  costs  of  COPD  resemble  the  results  of  our 
study; however contrary to our results, no significant 
differences has been determined between the costs of 
patients  with  history  of  more  than  two  hospitaliza-
tions in the past year and patients with history of two 
or less hospitalizations. In the light of these data and 
the data of our study, we suggest that decreasing the 
costs of ICU should have a very important role in de-
creasing the costs of COPD, although the number of 
patients hospitalized in the ICU is lower.  
COPD is often a disease of prolonged smokers 
and therefore might accompany several diseases as-
sociated  with  smoking  or  aging  [17].  COPD  itself 
might also lead to co-morbid conditions via systemic 
effects [18]. The risks of cardiovascular diseases, dia-
betes, anemia, pulmonary embolism [19] and respir-
atory  infections  [20]  are  increased  in  patients  with 
COPD. It has been determined that the risk of death 
due to AECOPD is strongly related with the presence 
of significant co-morbidities and need for ventilator 
support  [21].  In  AECOPD  requiring  hospitalization, 
chronic  renal  failure  predicts  in-hospital  mortality, 
post-discharge mortality or both, independently [22]. 
A prevalence of 23.1% has been determined in a pop-
ulation  of  312  hospitalized  COPD  patients  [23].  A 
prospective study performed on patients with COPD 
has reported that anemia is a risk factor for dyspnea, 
dysfunctional capacity and mortality [24]. Pneumonia 
is an important part of COPD burden [25]. In their 
study, Chen YH et al. have demonstrated that hyper-
tension  and  cor  pulmonale  increased  the  cost  of 
COPD significantly, and did not affect the cost of re-
nal failure in patients hospitalized for AECOPD [16]. 
Although chronic renal failure, anemia and HAP were 
determined as the factors increasing the costs in our 
study, Chen YH et al. have not examined the effects of 
anemia and pneumonia. Similarly, mean duration of 
hospitalization was 20.7 days in the same study; the 
rate of patients admitted to the ICU was 14.3%, the 
rate of NIMV was 21.8%, IMV was 9.3% and mortality 
rate was 7.2%. Hence a distribution pattern which was Int. J. Med. Sci. 2012, 9 
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quite different compared to the distribution features 
of our study was presented. We concluded that the 
contradictory  results  obtained  in  the  two  studies 
stemmed  from  these  differences  in  patient  distribu-
tion profiles.  
Smoking is the most important cause of COPD. 
The high number of non-smokers among COPD pa-
tients  was  a  significant  finding  in  our  study.  This 
might be partially explained by the presence of risk 
factors other than smoking (exposure to biomass, be-
ing  a  coal  heaver)  in  our  patient  population. 
Non-smoker  COPD  patients  included  in  our  study 
consisted of coal  miners in 20% and housewives in 
62%. Exposure to biomass has been determined to be 
at quite high rates among housewives in our country 
[26]. The mortality of COPD has been reported to be 
associated with smoking in 85% in males and 70% in 
females [27]. Several population studies have demon-
strated that quitting smoking allowed the annual rate 
of reduction in FEV1 to regress to the rate noted in 
never  smokers  [28].  Relationship  between  tobacco 
smoke and COPD total cost is very clear [29,30]. In 
our  study,  we  determined  that  the  costs  of  COPD 
were greater among patients who had smoked more. 
We believe the fight against smoking will not only 
decrease the costs of patients admitted for AECOPD, 
but  also  prevent  emergence  and  development  of 
COPD  and  thus  decrease  the  total  cost  of  COPD 
burden.  
All these studies suggest that the costs increase 
with  the  increasing  severity  of  COPD  (ICU,  NIMV, 
IMV etc.) or with progression to the next stage. Cur-
rently, the prevalence of COPD is increasing rapidly, 
although the prevalence of several other diseases has 
decreased [31]. Although the cost and prevalence of 
COPD, which is a preventable disease, is quite high, 
studies aimed at investigating the cost of COPD and 
the factors influencing this cost are quite inadequate. 
Efforts and expenditures aimed at preventing further 
worsening of COPD might decrease the cost of COPD 
at  any  stage.  In  this  study,  we  suggest  that  future 
costly measures of governments aimed at preventing 
the  emergence  or  progression  of  COPD  might  be 
“cost-effective”. 
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